Global Filariasis Treatment Market to Reach USD 28.68 Billion by 2032, Projected to Grow at 10.1% CAGR Through 2033

Global Filariasis Treatment Market

The global filariasis treatment market is expected to reach an impressive valuation of USD 10.96 Billion in 2023, with strong growth anticipated over the next decade. According to Future Market Insights, the market is projected to expand at a Compound Annual Growth Rate (CAGR) of 10.1% from 2023 to 2033.

Filariasis, a disease that disproportionately affects low-income populations and is a marker of underdevelopment, remains widespread in regions such as Africa and the developing world. The rise in filariasis cases is attributed to unplanned urban growth, which has led to an increase in mosquito breeding sites, further driving infection rates. Despite its severe economic and social impact, lymphatic filariasis continues to be one of the most common tropical diseases globally.

In India, Wuchereria bancrofti accounts for 99.4% of all cases, with the remaining 0.6% caused by Brugia malayi. The increasing prevalence of this debilitating disease underscores the urgent need for effective treatment solutions, fueling the demand for filariasis therapies and contributing to the market’s significant growth trajectory.

Because cities are growing unplanned and mosquito breeding sites are numerous, the prevalence of infection continues to increase. In spite of its serious economic and social consequences, lymphatic filariasis is one of the most prevalent tropical diseases worldwide. Only 0.6% of Indian cases are caused by Brugia malayi, while 99.4% are caused by Wuchereria bancrofti.

An MDA drive for eliminating filaria was conducted previously in 22 districts in Bihar. Local government health workers and Asha workers distributed the drug to every house in backward villages & small towns. ‘National Filaria Prevention Programme’ was launched by the Central government on March 23, 2020. Anti-filarial drugs are administered annually in a single dose (Mass Drug Administration – MDA) to prevent new infections and diseases.

Competitive Landscape

Research and development activities are underway by key players in the global filariasis treatment market in order to launch novel devices and therapeutics for the treatment of filariasis. In order to gain a competitive edge over their counterparts, companies aim to obtain approval for their new products in a timely manner.

• An LSTM-led partnership has begun its first human trial of a new drug that targets lymphatic filariasis and onchocerciasis. More than 150 million people worldwide suffer from lymphatic filariasis (LF) and onchocerciasis. In contrast to most parasitic worm drugs, AWZ1066S targets Wolbachia, a bacterial symbiont that is crucial to a parasitic worm’s survival. Through the direct involvement of Eisai Corp. Ltd., the progress of the drug candidate through the pipeline has been accelerated. This has resulted in the candidate being ready for the first clinical trial in humans.
• The Astellas Global Health Foundation has announced a five-year grant program worth $3.9 million that will provide grants to organizations working to improve the health of the Dominican Republic, Honduras, El Salvador, Guinea Bissau, Senegal, Kenya, and Uganda by improving access to health care, community resilience, and disaster support. Increasing access to health care, building resilient communities, and providing disaster support are just a few of the ways the Foundation’s grants will allow it to continue its work in low- and middle-income regions where Astellas has no presence.

A Full Report Overview

Key Companies Profiled

• Johnson & Johnson Private Limited
• Pfizer Inc.
• Elsai Co Ltd
• Atra Pharmaceuticals
• AbbVie Inc
• K.A. Malle Pharmaceuticals
• Unimark Remedies
• Cipla
• Bausch Health
• Novartis AG

Key Segments Profiled in the Filariasis Treatment Industry Survey?

By Type:

• Drugs
• Vaccine

By Application:

• Hospitals
• Clinics
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube